Gender differences in drug bioequivalence: Time to rethink practices

G. Koren; H. Nordeng; S. MacLeod

doi:10.1038/clpt.2012.233

Gender differences in drug bioequivalence: Time to rethink practices

G. Koren
, H. Nordeng
, S. MacLeod

Research output: Contribution to journal › Review article › peer-review

35 Scopus citations

Abstract

Currently, bioequivalence (BE) studies are carried out exclusively in males, assuming that intrasubject variabilities are similar between the sexes. This article challenges this hypothesis on the basis of available evidence and urges that studies of BE of sufficient power be undertaken in women also for all generic drugs aimed at women.

Original language	English
Pages (from-to)	260-262
Number of pages	3
Journal	Clinical Pharmacology and Therapeutics
Volume	93
Issue number	3
DOIs	https://doi.org/10.1038/clpt.2012.233
State	Published - Mar 2013
Externally published	Yes

Access to Document

10.1038/clpt.2012.233

Cite this

@article{a3addfee32d34fc0bcab48c1e4a686c3,

title = "Gender differences in drug bioequivalence: Time to rethink practices",

abstract = "Currently, bioequivalence (BE) studies are carried out exclusively in males, assuming that intrasubject variabilities are similar between the sexes. This article challenges this hypothesis on the basis of available evidence and urges that studies of BE of sufficient power be undertaken in women also for all generic drugs aimed at women.",

author = "G. Koren and H. Nordeng and S. MacLeod",

year = "2013",

month = mar,

doi = "10.1038/clpt.2012.233",

language = "אנגלית",

volume = "93",

pages = "260--262",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Gender differences in drug bioequivalence

T2 - Time to rethink practices

AU - Koren, G.

AU - Nordeng, H.

AU - MacLeod, S.

PY - 2013/3

Y1 - 2013/3

N2 - Currently, bioequivalence (BE) studies are carried out exclusively in males, assuming that intrasubject variabilities are similar between the sexes. This article challenges this hypothesis on the basis of available evidence and urges that studies of BE of sufficient power be undertaken in women also for all generic drugs aimed at women.

AB - Currently, bioequivalence (BE) studies are carried out exclusively in males, assuming that intrasubject variabilities are similar between the sexes. This article challenges this hypothesis on the basis of available evidence and urges that studies of BE of sufficient power be undertaken in women also for all generic drugs aimed at women.

UR - https://www.scopus.com/pages/publications/84874188816

U2 - 10.1038/clpt.2012.233

DO - 10.1038/clpt.2012.233

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 23299647

AN - SCOPUS:84874188816

SN - 0009-9236

VL - 93

SP - 260

EP - 262

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 3

ER -

Gender differences in drug bioequivalence: Time to rethink practices

Abstract

Access to Document

Other files and links

Fingerprint

Cite this